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Records from tea estates in the Kericho district in
Kenya show that malaria reemerged in the 1980s. Renewed
epidemic activity coincided with the emergence of chloro-
quine-resistant  Plasmodium falciparum malaria and may
have been triggered by the failure of antimalarial drugs.
Meteorologic changes, population movements, degradation
of health services, and changes in Anopheles vector popu-
lations are possible contributing factors. The highland
malaria epidemics of the 1940s were stopped largely by
sporontocidal drugs, and combination chemotherapy has
recently limited transmission. Antimalarial drugs can limit
the pool of gametocytes available to infect mosquitoes
during the brief transmission season.
E
pidemic malaria is a term applied to describe
Plasmodium falciparum transmission characteristics
of the highlands of East Africa and the Horn of Africa.
These areas are fringe regions between stable and unstable
transmission, which are affected to some degree by annual
variations in rainfall but primarily by low ambient temper-
ature. Such areas are often densely populated and of eco-
nomic and political importance because of their
agricultural potential. Much attention has been given to the
increasing frequency and clinical costs associated with
epidemics among highland populations in Africa (1–3). We
examine historical and contemporary data to define the
long-term epidemiologic transition of malaria in 1 district
of the western highlands of Kenya. We use these data in
support of our hypothesis that drug resistance is a key ele-
ment in highland malaria epidemics in East Africa, and we
examine how past control might guide future efforts to
reduce the clinical impact of epidemics.
Geography and Land Use
The Kericho district is located on the western side of
the Great Rift Valley in a highland area near Lake Victoria
(elevation 1,600–3,000 m above sea level) (Figure 1). The
soils are deep and well drained. Because of adequate and
reliable rainfall, the district can produce a surplus of crops
(forestry and horticultural products, pyrethrum, cereals,
fruit trees, tea). Tea is grown on self-contained farms,
called estates, that usually have ≈1,000 workers tending
<1 square mile of tea bushes. Two tea plantations (Figure
2), each consisting of 18 estates, employed 18,000–18,500
workers in 1998. Employees reside at the estate with 3 to
4 dependents each (4).
Migration and Mobility
Arrival of the railroad in the early 20th century and
improvement of roads facilitated movement from the
Kenyan coast and lake districts to the highlands, which
were thought free of malaria. European settlement began
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Oxford, United Kingdom Figure 1. Map of Kenya showing Nandi and Kericho districts.before World War I as an extension of other farming areas
in the Rift Valley. Alarge proportion of the tea estate labor
force were recruited from the Lake Victoria region (eleva-
tion <1,000 m) or from Kisii (elevation 1,500 m) in
Nyanza province. The Lake Victoria region is an area of
holoendemic malaria whose inhabitants often have asymp-
tomatic infections (5). Tea pickers are given 1 month leave
per year to return to their families in their natal village.
Over time, dependents of the tea pickers have come to live
on the estates. Travel back and forth from the highland
estates to the Lake Victoria lowlands is common (4).
Climate
Variations in climate affect the distribution and abun-
dance of malaria vectors. The effects of temperature on the
transmission cycle are manifold, but its specific effect on
sporogonic duration and mosquito survival is critical.
When the temperature is <18°C, transmission is unlikely
because few adult mosquitoes (0.28%) survive the 56 days
required for sporogony at that temperature and mosquito
abundance is limited by long larval duration. At 22°C,
sporogony is completed in <3 weeks, and mosquito sur-
vival is sufficiently high (15%) for the transmission cycle
to be completed. The potential number of infective mos-
quitoes reaches a peak at 30.6°C, after which it decreases
rapidly. The relationship between mosquito abundance and
rainfall is complex and best studied when temperature is
not limiting. Anopheles gambiae s.l. breed more prolifical-
ly in temporary and turbid water bodies, while in perma-
nent bodies predation is an important limitation. Rainfall is
a good indicator of vectors, their survival, and the poten-
tial for malaria transmission. Long-term, complete meteo-
rologic data are available from the Tea Research
Foundation. Analysis of the meteorologic relationships of
malaria in Kericho has been reported (6–8).
Health Service Provision and Drug Resistance
The public health sector in sub-Saharan Africa has been
overwhelmed by AIDS, lack of money, and other prob-
lems. In Kenya, population increases of 3% to 4% per year,
an inflationary economy in the face of fixed health service
wages, and administrative failures have depleted public
health services (9). However, this situation does not apply
to the tea plantations, where private agricultural companies
maintain a healthy, productive workforce (3). Whatever
the cause of recent increases in malaria in the western
highlands of Kenya, the tea plantation health systems have
continued identifying, counting, and treating malaria
infections among their workers. Since 2000, worker resi-
dences have been sprayed with insecticide every 4 months,
primarily for pest control. This measure is unlikely to have
differentially influenced the malaria data because both
plantations were using the same regimen.
Chloroquine was used to treat uncomplicated malaria
infections in Kenya from the 1950s until the national drug
policy was changed in 1998 (10). Chloroquine resistance
in Kenya was first documented in 1979 in a tourist who
had visited Kenya. After resistance became widespread
(11), chloroquine continued to be used as the first-line anti-
malarial drug for another 19 years. A 1985 survey indicat-
ed that parasites from the adjacent Nandi district were still
sensitive to chloroquine (12), whereas by 1996 chloro-
quine was unable to clear 50% of clinical infections in
children by day 7 (13).
Sources of Clinical Data since 1900
We used 3 principal sources of data. The first source was
reports in the Kenya national archives. The second was
local and international journal reports of malaria epidemics
in the region. The third was hospital data from 2 adjacent
tea plantations directly accessed to obtain the temporal and
secular patterns of malaria in Kericho. Inpatient data have
been located in admission registers of the hospital at tea
plantation 1 from 1965 to 2004 (3,14). The second tea plan-
tation hospital is adjacent to plantation 1 and since 1970 has
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Figure 2. Kericho, Kenya, tea plantation in 1998.maintained a weekly infectious disease notification system
that identifies all blood smear–positive malaria cases.
Although the system includes inpatients, it consists mostly
of outpatients. Although the 2 hospitals are adjacent, the
populations served are separated according to the company
of employment. Combined, these reports, data, and anec-
dotes build a qualitative and quantitative picture of Kericho
epidemics during the 20th century.
Epidemics
1918–1919 and 1928
During the 19th century, local malaria transmission was
nonexistent or negligible (15). Increasing trade and trans-
port led to major population movements from 1906
onwards. Movement of people associated with the opening
of civil and military posts probably introduced malaria into
the highlands. During World War I, soldiers from Kericho
were recruited to fight against the German forces in
Tanganyika. With troop demobilization and resettlement in
1918 and 1919, a malaria epidemic followed the influenza
pandemic (15). Further development in this region, includ-
ing the completion of the Ugandan railway from the Mau
escarpment to the malaria-endemic Lake Victoria region,
increased movement of people and parasites.
In 1928, an epidemic in Kericho district that involved
1,727 hospital case-patients occurred (15). Epidemics
were also reported in 1931, 1932, 1934, 1937, and 1940
(5). Malaria was much more severe in highland workers
than in their presumably functionally immune counterparts
from Lake Victoria (16). Health authorities used mass drug
administration for epidemic control, dispensing 57,600
ten-grain (600 mg) doses of quinine in 1 month (16).
1939–1948 and Introduction of Control
Epidemic malaria became a major infection on the tea
estates during World War II (17) because soldiers returning
from Ethiopia through the malarious coastal areas were
encamped along the adjacent railway (18). Epidemics
appeared to be caused by the large pool of parasitemic sol-
diers who infected the local mosquitoes during the brief
mid-year period suitable for malaria transmission at high
altitudes and occurred mostly within the military camp, the
township of Kericho, and the tea estates, while sparing
most “native reserve areas” (18). Removal of the military
camp at the end of the war did not stop the now indigenous
malaria transmission (17).
Given apparently fragile malaria transmission in the
agriculturally important western Kenyan highlands, inter-
ventions in Kenya were often first tried in Kericho.
Proguanil was a safe chemoprophylactic agent that had just
been developed as the result of an emergency wartime
project of the British and Australian armies. The medical
officer for plantation 1, D. Strangeways-Dixon, used mass
drug administration of proguanil, as the British army had
been doing in war areas (Figure 3) (17). In March 1948
(before the epidemic in the rest of the district), prophylac-
tic proguanil was given twice a week (a single 100-mg
tablet) to all plantation 1 employees and their dependents.
This strategy decreased malaria incidence in June and July
1948 (0.5 and 2.0 cases per 1,000 population, respectively,
compared with nearly 10 times that number the previous
year). Two rounds of house spraying with DDT in 1949
(March and June) complemented the prophylactic meas-
ures. During this period, malaria was virtually controlled.
Proguanil did not eliminate epidemics, however, and in
1952 the prolonged rainy season shifted the epidemic peri-
od from July to January, and malaria returned before the
start of proguanil prophylaxis. Reinstitution of proguanil
resulted in epidemic control, probably by blocking further
transmission.
Intermission, 1960–1980
Malaria in the Kericho district was largely imported by
persons traveling back from Lake Victoria. For the years in
which data were provided in the medical officer’s reports
(1966, 1967, 1970, 1975, and 1976), 95 deaths occurred
among 5,686 malaria patients admitted to Kericho district
hospital (case-fatality rate 1.7%). Recent studies on the
Kenyan coast showed an overall case-fatality rate of 3.5%,
varying greatly depending on the clinical syndrome that
caused hospitalization (19). At the Kericho tea estates,
malaria ceased to be a major problem from 1960 to 1980,
which roughly coincides with the period during which
chloroquine was fully effective against P. falciparum
malaria.
Reemergence of Seasonal Epidemics
In Kericho, annual mid-year malaria epidemics began
in 1990 at plantation 1, although epidemic peaks were evi-
dent in 1981 at plantation 2 (Figure 4). Increasing malaria
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Figure 3. Monthly malaria cases on the Kericho tea estates,
Kenya, 1942–1952, showing mass administration of proguanil.
Data were obtained from Strangeways-Dixon (17) and hospital
records.incidence was not related to overall warmer temperatures
but still depended on the annual pattern seen in the 1940s
in which malaria would increase after the rains in March
through April and decrease after the onset of cool weather
in July (8,9). Malaria admissions at plantation 1 increased
accordingly, from 5% of all admissions in 1970 to 47% in
1998 (Figure 5). However, before this increase, other
changes were noted such as increase in the percentage of
malaria inpatients of highland (>1,500 m) origin in 1981
and decrease in the adult-to-child ratio of inpatients in the
mid-1980s (Figure 5) (20). A high adult-to-child ratio of
malaria indicates a less immune population in which adults
become symptomatic when infected with malaria, which is
unusual in areas of high transmission (20). The case-fatal-
ity rate for malaria admissions at plantation 1 from 1965 to
1972 was 1.3%. The rate increased to 6% from 1990 to
1998, despite good medical and nursing inpatient care
(14). On the Kericho tea estates, most malaria deaths are
the result of severe anemia in young children, not cerebral
malaria (21). In other areas of Kenya, chloroquine resist-
ance increased case-fatality rates, and this trend could be
reversed by using more effective antimalarial drugs (22). 
Malaria incidence on the 2 adjacent tea plantations gen-
erally followed each other closely, despite separate worker
populations and medical systems. A striking divergence,
however, was noted in 2002, when heavy rains followed 2
years of low malaria incidence at both plantations because
of drought (Figure 6) (23). This difference was confirmed
when malaria incidence between outpatient malaria patient
visits at plantation 1 (4) and outpatient visits at the Kericho
district hospital were compared (24). Absence of increased
malaria at plantation 1 in 2002, while epidemic conditions
existed in both adjacent plantation 2 and the surrounding
district, is difficult to explain on the basis of weather,
human migration, medical access, or vector population
changes (24). One change that coincided with the abate-
ment of malaria at plantation 1 was a switch in first-line
malaria treatment for outpatients from chloroquine to sul-
fadoxine-pyrimethamine (SP) in 1999 (Figure 7). A
prospective malaria surveillance project involving febrile
outpatients on plantation 1 showed that after the substitu-
tion of SP for chloroquine, P. falciparum gametocyte rates
decreased in young children from 5% (1998) to <1%
(2002), while remaining unchanged in adults (<1%) (4).
This result occurred in the absence of any change in asex-
ual parasitemia (≈50% of febrile pediatric outpatients were
positive) over the same period. Although no simultaneous
surveillance of malaria parasites occurred at plantation 2,
which switched to SP in mid-2000, the appearance of epi-
demic malaria in the 1980s, as well as continued seasonal
malaria on plantation 2 after 2000, suggests that other fac-
tors contributed to local transmission. 
At least 3 chemotherapeutic explanations exist for pro-
gressive decrease in gametocytes on plantation 1 without a
significant effect on the percentage of febrile children with
asexual parasites. 1) Chloroquine-resistant P. falciparum
strains produce more gametocytes and infect more mos-
quitoes than chloroquine-sensitive strains, which may
explain why chloroquine resistance has spread rapidly
across Africa (25). The removal of chloroquine drug pres-
sure on plantation 1 in 1999 likely reduced the number of
infected mosquitoes. 2) Combination chemotherapy with
pyrimethamine increased from <20% of all treatment
courses on plantation 1 in 1998 to 85% of all treatment
courses by 2001. Pyrimethamine blocks the development
of parasites in the mosquito (26). Even increased numbers
of gametocytes produced after SP treatment are transmit-
ted poorly through the mosquito because of the antifolate
action of pyrimethamine (27,28). The sporontocidal effect
of the pyrimethamine component of SPis separate from its
ability to clear parasites from the blood. Pyrimethamine
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Figure 4. Monthly malaria incidence at 2 adjacent tea plantations
in Kericho, Kenya, 1970–2004. Plantation 1 data are from inpatient
admission registers, and plantation 2 data are from weekly malar-
ia slide reports that include outpatients.
Figure 5. Annual malaria inpatient characteristics from tea planta-
tion 1 in Kericho, Kenya, 1970–1999. Percentage of malaria
patients compared with percentage of all hospital admissions, per-
centage of malaria inpatients of highland (>1,500 m) family origin,
and ratio of adults to children (<15 years of age) of all malaria inpa-
tients are shown annually as collected from the same admission
registers. Gaps indicate missing data.had been used successfully as part of mass drug adminis-
tration to block transmission in the adjacent Nandi district
during the 1950s (29). 3) The use of artemisinin-contain-
ing combinations increased on plantation 1 from 3% of all
treatment courses in 2001 to 9% in 2002, whereas
artemisinin combinations represented <2% of all anti-
malarial drugs purchased at plantation 2 in 2002. From
2000 to 2002, 52% of hospitalized malaria patients at plan-
tation 1 received an artemisinin compound compared with
36% at plantation 2, but this percentage represented a rel-
atively small number of total malaria cases. Artemisinin
compounds killed gametocytes and blocked transmission
in Thailand (30) and The Gambia (31). Increased use of
artemisinin combinations primarily for sick children on
plantation 1 would have limited the pool of gametocytes
available to infect mosquitoes. The combined effect of dis-
continued chloroquine and increased use of SP and
artemisinin combinations resulted in too few infective
mosquitoes to start an epidemic during the brief highland
transmission season.
Combining the Evidence
Reemergence of mid-year malaria epidemics in the
western Kenyan highlands has progressed to annual inci-
dent peaks, which suggests that this area is now one of sea-
sonal rather than epidemic malaria (9,24). Reemergence is
the proper term because mid-year malaria increases were
common during World War II, and Kericho has not been
free of malaria for over 60 years (Figure 3). What has
changed to cause malaria to revert to its earlier pattern
after a long quiescence? Possible factors are changes in cli-
mate variability, population movements, decrease in qual-
ity of health services, changes in mosquito vectors, and
antimalarial drug resistance.
Doubts exist as to the plausibility of climate change as
proximate cause of epidemic malaria because global
warming cannot explain the World War II epidemics.
Dramatic increases in malaria during the 1990s are not
mirrored by prospectively collected climate data from
Kericho (7). No warming trend or increase in temperature
records that extend back nearly a century was observed at
several points in East Africa (8). Extensive comparison of
temperature, rainfall, and malaria records in Kericho after
1965 has not indicated any convincing multiple-year link
between either rainfall or temperature and malaria (32).
Furthermore, continent-wide trends in malaria transmis-
sion suitability during the 20th century do not show the
Kenyan highlands as an area of substantial change (33,34).
Malaria epidemics during World War II were probably
the result of population movement; stationing of soldiers in
Kericho after military operations in malarious areas start-
ed the epidemic. This epidemic was presumably the result
of the focal concentration of imported human gametocyte
carriers who infected mosquitoes during the brief mid-year
period when local transmission was possible. Extensive
travel between holoendemic Lake Victoria and Kericho
has occurred at least since World War II. Prospective data
suggest that persons returning from the malaria-endemic
lowlands transport malaria parasites up the mountain to
Kericho as asymptomatic or symptomatic infections (4).
Population movements alone cannot explain the lack of
substantial malaria from 1960 to 1980. Although popula-
tion movements are important in introducing malaria into
a malaria-free area, the highlands of western Kenya have
not been free of malaria infections since World War I.
In the last 25 years, Africa has seen a decrease in the
quality and quantity of public health services as result of
rapidly expanding population, decrease in purchasing
power of African currencies, severe institutional or organi-
zational problems, and increase in HIV infection. Yet
Kericho tea plantations have maintained high-quality
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Figure 6. Monthly malaria incidence at 2 adjacent tea plantations
in Kericho, Kenya, 1998–2004. Shown are the same data in Figure
4 in an expanded scale. See section on sources of clinical data
since 1900 to distinguish outpatient and inpatient composition.
Figure 7. Annual antimalarial drug purchases recorded in the
respective tea plantation hospital pharmacy records, Kericho,
Kenya, 1997–2002, showing the discontinuation of chloroquine as
sulfadoxine-pyrimethamine (SP) became first-line therapy.
Records of SP purchases at plantation 1 prior to 2001 were not
available.health services to a defined population (3). Whatever the
problems of the African district hospital, the interest of the
tea companies in maintaining healthy workers eliminates
decrease in healthcare services as an explanation of high-
land malaria epidemics.
Three entomologic surveys from 1946 to 1948 estab-
lished that An. gambiae is the principal vector in Kericho
with An. funestus playing a minor role (35). Investigations
from 1998 to 2000 to characterize the mosquito vectors on
the Kericho tea estates confirm the findings of Garnham
obtained >50 years ago (18), which indicated that small
numbers of An. gambiae in houses are malaria vectors (R.
Dunton, pers. comm.). Unpublished studies conducted by
Garnham on the same tea estates in the 1940s indicated
that residual insecticide spraying of house walls could be
very effective in controlling malaria. Modern vector con-
trol measures have not had any apparent differential effect
on malaria in the 2 plantations, but their potential has not
been fully explored. Similarly, long-lasting insecticide-
impregnated bed nets have not been systematically imple-
mented. Therefore, any major shift in species composition
of the malaria vectors is unlikely to have contributed to
malaria reemergence.
Drug resistance, specifically chloroquine resistance,
may be key in the increase of highland malaria. The peri-
od without major malaria epidemics in the Kenyan high-
lands extends from chloroquine introduction until
chloroquine resistance became widespread. Just as the par-
asites from nearby military camps caused the epidemics of
World War II, the inability of chloroquine to eliminate par-
asites recreated a similar situation during the 1990s in the
resident population. The increase in death rates of hospital-
ized malaria patients since 1990 also indicates chloroquine
resistance and has been observed in other parts of Africa
(36). Population increases that contribute to a decrease in
access to health care can explain some highland malaria
epidemiology, but this did not occur in Kericho, where
number of workers and resident dependents has been sta-
ble (20). Drug resistance to chloroquine remains the lead-
ing explanation for the reemergence of highland malaria in
the Kericho tea plantations and has been implicated in
nearby areas (37). The absence of an epidemic on planta-
tion 1 after use of more effective antimalarial drugs is
additional evidence that the prime factor influencing high-
land malaria in Kericho is antimalarial drug resistance.
Drug resistance is not a universal explanation for epidem-
ic malaria in the highlands of East Africa, especially given
the highly controlled nature of the tea estates, which is
atypical of rural Africa. Kabale, Uganda (38), and Nandi,
Kenya (39), are reminders that malaria is a focal disease
susceptible to many factors that vary by specific location
and season.
The Future
Increasing chloroquine failure rates directly influence
clinical outcomes and affect public health consequences in
areas of marginal malaria transmission, such as Kericho.
Small changes in the number of persons carrying infective
gametocytes can initiate malaria epidemics through
increased mosquito transmission. SP lowers transmission
pressure by curing more infections and decreasing the
infectivity of surviving gametocytes by the sporontocidal
action of pyrimethamine (26–28). However, SP fails to
cure uncomplicated malaria in East Africa and can only be
viewed as an interim replacement for chloroquine (40).
Appropriate case management of uncomplicated malaria is
still a valuable preventive measure for malaria epidemics.
The key point is to cure enough infections so that the
remaining parasites cannot rapidly expand during seasonal
transmission. Therefore, the choice of first-line malaria
chemotherapy is crucial to cure those treated, as well as
allow the maximum number of persons to be treated.
Epidemic-prone areas of marginal transmission are good
places to examine the public health consequences of treat-
ment options because a high proportion of infections
progress to symptomatic malaria. When multidrug-resist-
ant malaria was encountered on the Thailand–Burma bor-
der, the impending epidemic was aborted by use of
artemisinin combination therapy (ACT), which cured
patients and blocked transmission by killing gametocytes
(30). The most promising African example of ACT is from
KwaZulu-Natal, where malaria transmission on the South
Africa–Mozambique border was substantially blocked by
sequentially replacing chloroquine with SP and then with
ACTsupplemented with residual insecticide spraying (41).
Effective antimalarial drugs are not just good for sick
African children, they can also help decrease transmission
pressure in areas of seasonal transmission and stop the
increasingly steep spiral of drug resistance that has now
left sub-Saharan Africa without readily available treatment
for uncomplicated malaria. Effective drug combinations
are urgently needed not only to prevent African children
from dying of malaria, but also to prevent highland malar-
ia epidemics. 
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